Clinical Trials
66 trialsScreening for Hematology Branch Protocols
National Institutes of Health Clinical Center (CC)
Gulf Long-Term Follow-Up Study
National Institutes of Health Clinical Center (CC)
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
BRUIN-MCL-321
Eli Lilly and Company
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems
Universitair Ziekenhuis Brussel
APEX
Cogent Biosciences, Inc.
VENAZA-5S
University of Leipzig
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
National Institutes of Health Clinical Center (CC)
BRUIN CLL-321
Eli Lilly and Company
inMMyCAR
Kelonia Therapeutics, Inc.
Autologous Testicular Tissue Transplantation
Universitair Ziekenhuis Brussel
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
COMPLHEMATO
University Hospital, Limoges
BRUIN-CLL-314
Eli Lilly and Company
MagnetisMM-7
Pfizer
QUATRO-APL
Quetzal Therapeutics
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Medical College of Wisconsin
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
University of Southern California
CHIS
Assistance Publique - Hôpitaux de Paris
CLOVER-WaM
Cellectar Biosciences, Inc.
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIC
Takeda
MDS
Thomas Jefferson University
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
HORIZONS
Massachusetts General Hospital
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
BRUIN CLL-322
Eli Lilly and Company
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
CTL-DP 01
Nantes University Hospital
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
Brigham and Women's Hospital
ReSTORE
Herlev and Gentofte Hospital
BRUIN CLL-313
Eli Lilly and Company
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Stanford University
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Fred Hutchinson Cancer Center